Lead: On Dec. 7, 2025, a federal advisory panel voted to end the long-standing recommendation that all newborns receive the hepatitis B vaccine at birth, a decision that has left many parents unsettled and health groups alarmed. The meeting of the Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices was chaired by Dr. Robert Malone and produced a policy change that critics say reverses decades of practice. Parents such as Eleanor Trenary of St. Paul, whose daughter is six weeks old, say the change adds anxiety to early parenthood as official guidance and trust in agencies shift. The vote is the first visible move after Health Secretary Robert F. Kennedy Jr. overhauled the committee earlier this year.
Key Takeaways
- On Dec. 7, 2025, ACIP voted to end the universal newborn hepatitis B vaccination recommendation that had been in place for decades.
- Dr. Robert Malone chaired the CDC advisory meeting where the vote took place; the change follows a June personnel shake-up in which 17 committee members were dismissed and replaced.
- Public health groups including the American Academy of Pediatrics and the American Medical Association publicly disagreed with the committee’s decision within hours of the vote.
- Medical evidence cited historically shows near-elimination of perinatal hepatitis B transmission in the U.S. after universal birth dosing, a public-health achievement cited by critics of the change.
- The Department said the policy shift is not expected to remove insurance coverage for individuals who opt for the birth dose independently.
- Officials signaled the committee will review the larger childhood vaccine schedule in the coming months, raising the prospect of further revisions.
- Parents report increased confusion and stress; some say political influence, rather than new science, appears to be driving policy changes.
Background
The hepatitis B vaccine at birth has been a routine part of the U.S. childhood immunization schedule for decades, aimed at preventing perinatal transmission from mother to infant and reducing long-term liver disease. Widespread uptake of the birth dose and subsequent infant doses contributed to a dramatic drop in hepatitis B infections among young children, which public-health agencies have characterized as a major success. The Advisory Committee on Immunization Practices, or ACIP, advises the CDC on vaccine policy; its recommendations have historically shaped standard practice and insurance coverage decisions. In June 2025, Health Secretary Robert F. Kennedy Jr. removed all 17 existing ACIP members and appointed a new panel whose members have expressed varying levels of skepticism toward current vaccine policy. That personnel shift preceded the vote that removed the universal birth recommendation.
The decision arrives against a backdrop of heightened public scrutiny of federal health guidance and rising political polarization around medical policy. Professional medical organizations typically evaluate ACIP proposals and issue their own guidance; in this case both the American Academy of Pediatrics and the American Medical Association immediately voiced opposition. For many clinicians, the change forces an adjustment in counseling new parents and in clinical workflows in labor-and-delivery and pediatric settings. For parents, particularly first-time parents, the new guidance replaces a long-standing point of clarity with a set of choices that can be confusing at a time already marked by sleep deprivation and intense concern for infant safety.
Main Event
At a Friday meeting of the CDC advisory committee on Dec. 7, 2025, members voted to rescind the blanket recommendation that newborns receive hepatitis B vaccination at birth. Dr. Robert Malone chaired the session; the committee framed the vote as a reconsideration of when and whom to vaccinate rather than an outright removal of access to the vaccine. Committee members and staff discussed alternate strategies such as targeted vaccination based on maternal testing and perinatal risk factors.
The vote prompted swift pushback from major medical organizations. The American Academy of Pediatrics and the American Medical Association each issued statements disagreeing with the committee’s action and urging continued emphasis on strategies that had previously reduced infant hepatitis B cases to very low levels. Hospital epidemiologists warned that changing a decades-old default could increase missed opportunities for newborn vaccination in busy maternity settings.
Parents described immediate confusion. Eleanor Trenary, 35, of St. Paul, said she trusted prior CDC recommendations and now worries about obtaining consistent protection for her newborn and any future children. Clinicians explained that, while the change does not make the vaccine unavailable, it transfers more decision-making to parents and providers during the perinatal period, creating variability in uptake.
Health officials noted that insurance coverage for those who choose the neonatal dose is expected to continue, though insurers’ responses will be watched closely. Committee members signaled that the panel will continue reviewing other vaccines on the childhood schedule, meaning additional policy shifts could follow in the months ahead.
Analysis & Implications
Removing a universal birth recommendation shifts the balance from a population-level default toward individualized decision-making. Historically, universal newborn dosing reduced reliance on perfect prenatal screening and on consistent access to postnatal follow-up, both of which can be uneven across populations. Targeted approaches depend on reliable prenatal maternal testing and robust follow-up systems; gaps in those systems could lead to higher rates of perinatal transmission among vulnerable groups.
The political context matters for public confidence. The June dismissal of ACIP’s membership by the Health Secretary has already altered how stakeholders interpret committee actions; many clinicians and professional societies now approach ACIP recommendations with increased skepticism. That erosion of trust may reduce adherence to federal guidance more broadly and complicate public-health messaging during outbreaks or routine prevention efforts.
From a health-systems perspective, hospitals and birthing centers must weigh new administrative burdens: updating standing orders, revising consent forms, and retraining staff on counseling for the neonatal period. Insurers’ operational decisions on coding and reimbursement will also be pivotal; even if official statements promise continued coverage for voluntary doses, practical barriers—prior authorization, billing changes, or shifting formularies—could affect access.
Internationally, the move may stand out. Most high-income countries maintain neonatal hepatitis B strategies tied to local epidemiology; shifting away from a universal birth dose in the U.S. could complicate comparability with global immunization benchmarks and affect U.S. public-health relationships with partners that emphasize birth dosing as a means to eliminate perinatal hepatitis B transmission.
Comparison & Data
| Policy Element | Before Dec. 7, 2025 | After Dec. 7, 2025 |
|---|---|---|
| Newborn Hepatitis B Dose | Universal recommendation at birth | Universal recommendation rescinded; targeted approaches considered |
| Perinatal Hepatitis B Cases (U.S.) | Nearly eliminated among newborns after decades of universal dosing | Future trend uncertain; monitoring planned |
| Committee Composition | ACIP membership established before June 2025 | All 17 prior members replaced in June 2025 |
The table summarizes the immediate contrast between the prior standard and the committee’s new position. While precise numerical projections of disease impact are not yet available, public-health experts warn that targeted strategies generally require higher-quality screening and follow-up to achieve the same near-elimination outcomes that universal birth dosing produced.
Reactions & Quotes
The policy change prompted rapid responses from multiple quarters, mixing professional concern with parental anxiety and political commentary.
“It feels like a brave new world to not trust CDC recommendations anymore. All of us just want to do what we can to keep our kids safe,”
Eleanor Trenary, new parent, St. Paul
Trenary’s remark captures the sentiment among many new parents who relied on a predictable schedule of newborn care. Health systems emphasize that clinicians will need to spend more time explaining options during postpartum visits and at discharge.
“The prior universal birth dose was a cornerstone of preventing perinatal hepatitis B; changing that default risks reversing public-health gains,”
Statement summarized from the American Academy of Pediatrics (medical association)
The AAP’s and AMA’s critiques focused on the epidemiologic record and the practical challenges of shifting clinical defaults. Government officials argued the vote reflects a review of data and approaches, while acknowledging the need for further communication to providers and the public.
Unconfirmed
- Whether insurers will uniformly maintain current coverage practices for voluntary neonatal hepatitis B doses is not yet confirmed and may vary by carrier.
- Specific details about how other childhood vaccine recommendations will change as the committee reviews the schedule remain undetermined.
- Attribution of the committee’s vote solely to political motivations, rather than a combination of evidence review and policy judgment, is not definitively established.
Bottom Line
The Dec. 7, 2025 vote to rescind universal newborn hepatitis B vaccination guidance marks a notable shift in U.S. vaccine policy with immediate effects on clinical practice and parental decision-making. Although the vaccine remains available, the move replaces a clear default that helped bring perinatal hepatitis B cases to very low levels, and it places greater reliance on prenatal screening and follow-up systems whose coverage is unequal.
For parents and clinicians, the near-term priorities are clear: improve communication at the bedside, ensure prenatal testing and documentation are robust, and monitor insurer responses to maintain practical access. Over the coming months, observers should watch for formal CDC guidance updates, professional-society recommendations, insurer policies, and any early surveillance signals of changing hepatitis B incidence among infants.
Sources
- The New York Times — News report on ACIP vote and reactions (news)
- Centers for Disease Control and Prevention — ACIP information and meeting materials (official advisory)
- American Academy of Pediatrics — Organization homepage and clinical policy resources (professional medical association)
- American Medical Association — Organization homepage and policy statements (professional medical association)